Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single pill after sex stop STIs in women?

NCT ID NCT07704957

Prevention Sponsor: Tulane University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial tests whether taking a single dose of the antibiotic doxycycline within 24 hours of condomless sex can prevent bacterial sexually transmitted infections (STIs) like chlamydia, gonorrhea, and syphilis in women aged 18–35 at increased risk. Participants are randomly assigned to receive doxycycline or standard care, and researchers track how many new STIs occur over time. If it works, this approach could offer a new prevention tool for women.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline taken as a single 200 mg dose within 24 hours of condomless sex
What this could lead to
If effective, this could give women a simple, on-demand pill to prevent common bacterial STIs, reducing infections and related health problems.
What could go wrong
A previous trial in women found no benefit, so results may not be positive. The study is open-label, which can bias outcomes, and long-term antibiotic use raises concerns about resistance and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 519 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Apr 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female * Aged 18-35 * Reporting condomless vaginal sex with men AND least one of the following: 1. diagnosis of CT, gonorrhea, syphilis, or trichomonas in the past year 2. reporting 2 or more sexual partners in the past 6 months * Plan to continue to be sexually active over the next year * Have smartphone and be willing to engage with an app * If HIV+: Viral load\<200 copies/ml and CD4 count \>200 cells/mm3 Exclusion Criteria: * Pregnant, nursing, or intending to become pregnant * Reported allergy to tetracyclines * Liver disease or end-stage renal disease * Non-English Speaking * Taking concomitant medications which may impact doxycycline metabolism (e.g., systemic retinoids, antacids, barbiturates, carbamazepine, phenytoin, iron, warfarin, rifampin) * Not willing to take doxy PEP or comply with study procedures * Unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chlamydia trachomatis infectious disease prevention target gonorrhea prevention target syphilis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adherence Chlamydia females Gonorrhea female Prevention Prophylaxis Syphilis female

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.